文献速递消化道肿瘤放疗

局部晚期直肠癌术前IMRT同步整合加量联合卡培他滨的多中心短期结果

Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study.
PubMed 文献 · Radiat Oncol · 2017-08-22

该多中心回顾性研究分析76例局部晚期直肠癌患者,术前接受IMRT同步整合加量(全盆腔45 Gy,瘤床中位54 Gy,范围52.5-57.5 Gy)联合卡培他滨化疗。74/76(97.4%)完成放疗,64/76(84.2%)完成化疗,8例(10.5%)出现3-4级急性毒性。72例接受手术,肿瘤和淋巴结降期率分别为70.8%和67%,病理完全缓解率27.8%,手术并发症18.1%。结论认为该方案可行、耐受良好且有效。

要点

  • IMRT-SIB联合卡培他滨术前治疗LARC可行,97.4%完成放疗。
  • 3-4级急性毒性发生率10.5%,耐受性良好。
  • 病理完全缓解率27.8%,肿瘤降期率70.8%。

核心结论

  • IMRT-SIB剂量52.5-57.5 Gy(中位54 Gy)联合卡培他滨术前治疗LARC可行、耐受良好,在降期和病理完全缓解方面有效。

研究设计与样本

  • 多中心回顾性分析,纳入五个意大利放疗中心收治的76例局部晚期直肠癌患者。

主要发现

  • 74/76(97.4%)完成计划放疗,64/76(84.2%)完成计划化疗。
  • 8例(10.5%)出现3-4级急性毒性。
  • 72/76例接受手术,肿瘤降期51例(70.8%),淋巴结降期43例(67%)。

关键数值与推荐

  • 全直肠系膜和盆腔淋巴结处方剂量45 Gy,肿瘤及相应直肠系膜SIB中位剂量54 Gy(范围52.5-57.5 Gy)。
  • 急性毒性按CTC-AE 4.0标准评估。

临床怎么用

  • 对于局部晚期直肠癌术前治疗,可考虑IMRT-SIB联合卡培他滨方案,但需注意远期毒性和生存影响尚待更长随访评估。

局限性

  • 回顾性设计,样本量76例,随访时间短,长期毒性及对疾病控制和生存的影响尚未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preoperative radiotherapy (RT) in combination with fluoropyrimidine-based chemotherapy (CT) is the standard of care in patients with locally advanced, T3-T4 N0-2, rectal cancer (LARC). Given the correlation between RT dose-tumor response and the prognostic role of the tumor regression grade (TRG), treatment intensification represents an area of active investigation. The aim of the study was to analyze the role of RT dose-intensification in the preoperative treatment of LARC in terms of feasibility, efficacy and toxicity. METHODS: We retrospectively analyzed patients with LARC treated with intensity-modulated radiotherapy (IMRT) and simultaneous integrated boost (SIB) at five Italian radiation oncology centers. Concurrent Capecitabine was administered. Treatment response was evaluated in terms of disease down-staging and TRG. Acute toxicity was evaluated according to the CTC-AE 4.0 scale. RESULTS: A total of 76 patients were identified for this analysis. A dose of 45 Gy was prescribed to the entire mesorectum and pelvic lymph nodes with a median SIB dose of 54 Gy (range 52.5-57.5) to the tumor and corresponding mesorectum. Overall, 74/76 (97.4%) patients completed the planned RT, whereas 64/76 (84.2%) patients completed the prescribed CT. Eight (10.5%) patients developed grade 3-4 acute toxicity. Overall, 72/76 patients underwent surgery. The tumor and nodal down-staging was documented in 51 (70.8%) and 43 (67%) patients, respectively. Twenty (27.8%) patients obtained a pathologic complete response. Surgical morbidity was reported in 13/72 patients (18.1%). CONCLUSIONS: Although retrospective in design, this study indicates that IMRT-SIB with a dose range of 52.5-57.5 Gy (median 54 Gy) and concomitant Capecitabine appears feasible, well tolerated and effective in terms of disease down-staging and pathological complete response. Long-term toxicity and the impact on disease control and patient survival will be evaluated with a longer follow-up time. TRIAL REGISTRATION: NA.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lupattelli M, Matrone F, Gambacorta MA, et al. Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study. Radiat Oncol. 2017. PMID: 28830475. doi:10.1186/s13014-017-0870-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。